Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04679870 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis
A Phase 2 study of Myelofibrosis, sponsored by Galecto Biotech AB.
- Active
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 11
- Study locations
NCT04679870 is a Phase 2 study of Myelofibrosis that is active but no longer recruiting, run by Galecto Biotech AB. The registered enrollment target is 21 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The trial reports 11 study locations across 2 states.
The verdict
NCT04679870, a Phase 2 study of Myelofibrosis, is active but no longer recruiting, sponsored by Galecto Biotech AB.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study is an open label, phase IIa trial in subjects with Myelofibrosis
Conditions Studied
Interventions
- DRUG GB2064
Study Locations (11)
Other
- Woden Dermatology - Canberra
- Heinrich-Heine-University Dusseldorf - Düsseldorf
- Universitätsklinikum Heidelberg - Heidelberg
- Universität Leipzig - Leipzig
- Klinikum rechts der Isar der Technischen Universitaet Munchen - München
- University of Bologna Sant Orsola Malpighi - Bologna
- Azienda Ospedaliero-Universitaria Careggi - Florence
- ASST Grande Ospedale Metropolitano Niguarda - Milan
- Azienda Ospedaliero-Universitaria San Luigi Gonzaga di Orbassano - Orbassano
- Azienda Socio-Sanitaria Territoriale dei Sette Laghi - Varese
Texas
- MD Andersson Cancer Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-06-09 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04679870
The ClinicalTrials.gov registry entry for NCT04679870 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The listed sponsor is Galecto Biotech AB, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which GB2064 is the first listed.
NCT04679870 reports 11 study locations spanning 2 distinct geographic areas - top geographies include Other, Texas.
Frequently Asked Questions
What is clinical trial NCT04679870 about?
NCT04679870 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis". This study is an open label, phase IIa trial in subjects with Myelofibrosis
What is the current status of trial NCT04679870?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2021-06-09. Estimated completion is 2026-06-30.
What conditions does trial NCT04679870 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT04679870?
The interventions under investigation include: GB2064 (DRUG).
Who is sponsoring clinical trial NCT04679870?
This trial is sponsored by Galecto Biotech AB, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04679870 being conducted?
This trial has 11 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.